Home > Boards > US Listed > Biotechs > Aurinia Pharmaceuticals Inc (AUPH)

Just to review, from the conference call:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Churchill54 Member Profile
 
Followed By 1
Posts 50
Boards Moderated 0
Alias Born 08/02/17
160x600 placeholder
Aurinia Pharmaceuticals reverses decline after report on potential M&A interest Seeking Alpha - 1/13/2022 2:49:28 PM
Aurinia Pharmaceuticals drops amid silence on M&A after conference presentations Seeking Alpha - 1/13/2022 12:57:53 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 1/7/2022 4:11:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2022 4:19:20 PM
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences Business Wire - 1/4/2022 4:17:00 PM
ICE Biotech index rejig: AUPH, AVXL among added; AMRS, GH among deleted Seeking Alpha - 12/17/2021 11:54:46 AM
Aurinia: Long Term Prospects Are Sound, Says Oppenheimer TipRanks - 12/13/2021 3:14:19 PM
Aurinia Pharma upgraded at Oppenheimer; ongoing M&A story noted Seeking Alpha - 12/10/2021 8:23:48 AM
Aurinia Pharmaceuticals nearing highs on report about M&A process Seeking Alpha - 12/9/2021 1:25:51 PM
Aurinia gains 7% on positive Lupkynis data in lupus nephritis study Seeking Alpha - 12/9/2021 6:30:44 AM
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN) Business Wire - 12/9/2021 6:15:00 AM
Aurinia Pharmaceuticals gains amid takeover speculation Seeking Alpha - 12/2/2021 11:06:41 AM
Aurinia falls 28% amid mixed shelf offering, skepticism on buyout rumors Seeking Alpha - 11/22/2021 12:43:00 PM
Aurinia Pharmaceuticals drops 12% after filing mixed shelf offering Seeking Alpha - 11/19/2021 5:26:12 PM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 11/19/2021 5:05:35 PM
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference Business Wire - 11/10/2021 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/3/2021 4:21:48 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/3/2021 4:14:03 PM
Aurinia Pharma slips as uptake of lupus nephritis therapy slows Seeking Alpha - 11/3/2021 8:28:18 AM
Aurinia Pharma EPS misses by $0.06, beats on revenue Seeking Alpha - 11/3/2021 6:11:29 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/3/2021 6:02:00 AM
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates Business Wire - 11/3/2021 6:00:00 AM
Aurinia Pharma Q3 2021 Earnings Preview Seeking Alpha - 11/2/2021 11:59:17 AM
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis Business Wire - 11/1/2021 10:12:00 AM
Aurinia Pharma drops after GlaxoSmithKline denies report on potential bid Seeking Alpha - 11/1/2021 10:01:23 AM
Churchill54   Monday, 11/23/20 02:34:02 PM
Re: None
Post # of 14697 
Just to review, from the conference call: Benlysta is no competition, pricing for Voc may be at the high end of expectations, the label should support IP 2037, the company may be acquired but not given away, expect partnerships for non US sales. I expect a 4-6 billion buyout in 2021 which is 30-45. That’s worth the daily bs manipulation which I expect to continue until and maybe beyond approval. I don’t think we see single digits once we are approved but that’s a possibility before approval. I am in this for the buyout and wouldn’t consider selling under 30 which isn’t likely to happen without a buyout. Auph is a great buy now with a minimal amount of risk. Don’t be discouraged by the resident jerk who lives to add angst on every downturn. He was wrong on Ariad and will be wrong here as well, a total loser.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences